Research Papers

Comprehensive review of BPC-157's gastroprotective mechanisms. Covers protection from ethanol, NSAIDs, and stress-induced ulcers in rodent models. Documents NO-pathway involvement and cytoprotective effects across multiple GI tissues.

Rodent study demonstrating accelerated Achilles tendon healing following BPC-157 treatment. Histology showed improved tendon organization and mechanical strength versus control. Established BPC-157 as a promising soft tissue repair agent.

Phase I/II human trial demonstrating that CJC-1295 DAC produces sustained GH and IGF-1 elevation for up to 6 days after a single dose. Dose-dependent increases observed. Well tolerated with minimal adverse effects across all dose groups.

Landmark RCT (n=1961) showing that weekly 2.4mg semaglutide resulted in mean body weight reduction of 14.9% vs. 2.4% placebo over 68 weeks. Significant improvements in cardiometabolic risk factors. Established semaglutide as a major advance in obesity pharmacotherapy.

Large-scale cardiovascular outcomes trial (n=17,604) demonstrating semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease. First GLP-1 agonist trial to show cardiovascular benefit independent of diabetes status.

Review article summarizing GHK-Cu's role in skin repair. Covers upregulation of collagen I, II, and III synthesis, stimulation of wound contraction, and broad gene regulatory effects affecting over 4,000 human genes. Discusses topical and systemic applications.